Allogene expands collaboration with Foresight for MRD companion diagnostic; commits $37.3M

Allogene Therapeutics, Inc.

Amended agreement covers MRD assay development as companion diagnostic for cema-cel in EU, UK, Canada, Australia.
Allogene to fund approximately $37.3 million for assay development, milestone payments, and clinical sample testing.
Parties will use commercially reasonable efforts to obtain regulatory approval for respective products.
Each party retains ownership of its background IP and improvements; termination rights unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.